Wintest
6721
Osaka Yuka Industry
4124
D. Western Therapeutics Institute
4576
Asiro
7378
Hamee
3134
(Q2)Mar 31, 2024 | (Q1)Dec 31, 2023 | (FY)Sep 30, 2023 | (Q4)Sep 30, 2023 | (Q3)Jun 30, 2023 | (Q2)Mar 31, 2023 | (Q1)Dec 31, 2022 | (FY)Sep 30, 2022 | (Q4)Sep 30, 2022 | (Q3)Jun 30, 2022 | |
---|---|---|---|---|---|---|---|---|---|---|
Total revenue | 6.64%1.14B | 3.42%1.74B | 15.93%5.41B | 8.64%1.32B | 15.81%1.33B | -6.95%1.07B | 46.68%1.69B | 25.54%4.66B | 21.48%1.21B | 15.61%1.15B |
Cost of revenue | -11.25%370.56M | -2.15%590.36M | 20.53%1.95B | 1.72%470.21M | 22.24%461.88M | 7.54%417.52M | 53.96%603.35M | 29.04%1.62B | 38.16%462.27M | 19.42%377.84M |
Gross profit | 18.03%774.27M | 6.52%1.15B | 13.47%3.45B | 12.90%847.41M | 12.66%867.2M | -14.30%655.99M | 42.92%1.08B | 23.76%3.04B | 13.07%750.59M | 13.83%769.76M |
Operating expense | 2.72%531.96M | 16.83%654.76M | 16.45%2.44B | 26.33%752.43M | 24.48%605.7M | -6.36%517.89M | 22.64%560.44M | 15.41%2.09B | 1.72%595.61M | -5.19%486.57M |
Operating profit | 75.46%242.3M | -4.53%498.89M | 6.92%1.02B | -38.71%94.98M | -7.66%261.49M | -34.96%138.1M | 73.73%522.54M | 47.17%951.29M | 97.89%154.98M | 73.67%283.19M |
Net non-operating interest income (expenses) | 261.54%315K | 0 | 18.18%-720K | 55.09%-128K | 51.06%-162K | -224.20%-195K | 44.18%-235K | 92.56%-880K | 95.48%-285K | 91.25%-331K |
Non-operating interest income | --315K | --0 | --0 | --0 | --0 | --0 | --0 | 53,100.00%532K | --0 | --0 |
Non-operating interest expense | --0 | --0 | -49.01%720K | -55.09%128K | -51.06%162K | -48.00%195K | -44.18%235K | -51.66%1.41M | -43.11%285K | -51.54%331K |
Net investment income | 53.66%-329K | -64.70%539K | -28.08%251K | 42.07%949K | 49K | -710K | 183.83%1.53M | 206.14%349K | 5,972.73%668K | |
Gain(Loss) on financial instruments designated as cash flow hedges | ||||||||||
Gain(Loss) on derecognition of available-for-sale financial assets | ||||||||||
Income from associates and other participating interests | ||||||||||
Special income (charges) | 15.79%-9.67M | 1.79%-11.49M | ||||||||
Less:Other special charges | ---- | ---- | ---- | ---- | ---- | ---- | ---- | -134.64%-248K | ---- | ---- |
Less:Write off | ---- | ---- | -17.57%9.67M | ---- | ---- | ---- | ---- | 6.88%11.74M | ---- | ---- |
Other non-operating income (expenses) | 78.77%379K | -97.05%301K | 197.68%11.05M | -4.46%386K | 34.59%249K | -82.39%212K | 431.68%10.2M | 164.37%3.71M | 132.66%404K | -38.54%185K |
Income before tax | 76.11%243.33M | -6.19%498.86M | 7.85%1.02B | -40.39%85.82M | -7.47%262.53M | -35.50%138.16M | 75.93%531.8M | 52.87%944.16M | 140.23%143.97M | 77.78%283.71M |
Income tax | 32.11%76.2M | -3.59%160.88M | 11.86%373.3M | -31.62%47.14M | 2.65%101.62M | -17.86%57.68M | 74.62%166.87M | 69.29%333.71M | 339.97%68.93M | 88.73%99M |
Net income | 107.65%167.13M | -7.39%337.98M | 5.66%645.02M | -48.45%38.68M | -12.88%160.92M | -44.10%80.49M | 76.53%364.93M | 45.17%610.45M | 69.53%75.04M | 72.42%184.72M |
Net income continuous operations | 107.65%167.13M | -7.39%337.98M | 5.66%645.02M | -48.45%38.68M | -12.88%160.92M | -44.10%80.49M | 76.53%364.93M | 45.17%610.46M | 69.53%75.04M | 72.42%184.72M |
Noncontrolling interests | ||||||||||
Net income attributable to the company | 107.65%167.13M | -7.39%337.98M | 5.66%645.02M | -48.45%38.68M | -12.88%160.92M | -44.10%80.49M | 76.53%364.93M | 45.17%610.45M | 69.53%75.04M | 72.42%184.72M |
Preferred stock dividends | ||||||||||
Other under preferred stock dividend | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Net income attributable to common stockholders | 107.65%167.13M | -7.39%337.98M | 5.66%645.02M | -48.45%38.68M | -12.88%160.92M | -44.10%80.49M | 76.53%364.93M | 45.17%610.45M | 69.53%75.04M | 72.42%184.72M |
Gross dividend payment | ||||||||||
Basic earnings per share | 107.27%18.53 | -7.98%37.48 | 5.08%71.84 | -49.16%4.25 | -13.43%17.92 | -44.61%8.94 | 75.79%40.73 | 33.17%68.37 | 93.99%8.36 | 54.57%20.7 |
Diluted earnings per share | 108.30%18.31 | -7.26%37.05 | 5.67%70.63 | -48.23%4.25 | -12.80%17.64 | -44.26%8.79 | 76.54%39.95 | 33.65%66.84 | 90.51%8.21 | 62.39%20.23 |
Dividend per share | 0 | 0 | 25.00%20 | 25.00%20 | 0 | 0 | 0 | 33.33%16 | 33.33%16 | 0 |
Currency Unit | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY |
Accounting Standards | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP |